Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method
Acta Neuropathologica · 2025
DOI: 10.1007/s00401-024-02842-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2025. Verfasst von Sibylle Madlener und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Brain Neoplasms, Biomarkers, Tumor, Glioma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: City of Vienna Fund for innovative interdisciplinary Cancer Research, Austrian Science Fund, Oncomine Clinical Research Grant.
Abstract (Originalsprache)
Gliomas are the most common brain tumor type in children and adolescents. To date, diagnosis and therapy monitoring for these tumors rely on magnetic resonance imaging (MRI) and histopathological as well as molecular analyses of tumor tissue. Recently, liquid biopsies (LB) have emerged as promising tool for diagnosis and longitudinal tumor assessment potentially allowing for a more precise therapeutic management. However, the optimal strategy for monitoring gliomas by LB remains to be determined. In this study, we analyzed circulating tumor DNA (ctDNA) from 78 liquid biopsies (plasma n = 44, cerebrospinal fluid n = 34 (CSF)) of 35 glioma patients, determining H3F3A K28M (K27M) and BRAF V600E mutation allele frequency using droplet digital PCR (ddPCR). All results were correlated to clinically relevant parameters including diagnostic imaging and CSF aspiration site (ventricular vs lumbar) with respect to tumor localization. Regarding diagnostic accuracy, the calculated sensitivity score in the H3F3A K27M cohort was 84.61% for CSF and 73.68% for plasma. In the BRAF V600E cohort, we determined a sensitivity of 83.3% in plasma and 80% in CSF. The overall specificity was 100%. With respect to the CSF aspiration, the intra-operatively obtained CSF demonstrated 100% detection rate, followed by ventricular CSF obtained via Ommaya Reservoir/shunt puncture (93%) and CSF obtained via lumbar puncture (66%). Notably, this further correlated with the proximity of the CSF site to tumor localization. Longitudinal CSF monitoring demonstrated a good correlation to clinical and radiological disease evolution. Importantly, we show for the first time that monitoring BRAF V600E by ddPCR could serve as treatment response assessment in gliomas. In summary, our observation may inform recommendations with regard to location of CSF aspiration when incorporating LB into future treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
- Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Biology, Faculty of Medicine and Central, European Institute of Technology, Masaryk University, Brno, Czech Republic.
- Center for Precision Medicine, University Hospital Brno, Brno, Czech Republic.
Förderung
- City of Vienna Fund for innovative interdisciplinary Cancer Research
- Austrian Science Fund
- Oncomine Clinical Research Grant
- Physician Researcher Pathway Scholarships of the Medical University of Vienna
- Verein unser_kind
- Forschungsgesellschaft für Cerebrale Tumore
- Medical University of Vienna
Zitieren
APA
Madlener, S., Stepien, N., Senfter, D., Mayr, L., Laemmerer, A., Hedrich, C., Baumgartner, A., Lötsch-Gojo, D., Sterba, J., Pokorna, P., Kiesel, B., Widhalm, G., Eckert, F., Preusser, M., Rössler, K., Azizi, A., Peyrl, A., Czech, T., Haberler, C., …, & Gojo, J. (2025). Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02842-7
Vancouver
Madlener S, Stepien N, Senfter D, Mayr L, Laemmerer A, Hedrich C, et al. Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method. Acta Neuropathologica. 2025. doi:10.1007/s00401-024-02842-7
BibTeX
@article{Madlener2025,
author = {Madlener, Sibylle and Stepien, Natalia and Senfter, Daniel and Mayr, Lisa and Laemmerer, Anna and Hedrich, Cora and Baumgartner, Alicia and Lötsch-Gojo, Daniela and Sterba, Jaroslav and Pokorna, Petra and Kiesel, Barbara and Widhalm, Georg and Eckert, Franziska and Preusser, Matthias and Rössler, Karl and Azizi, Amedeo and Peyrl, Andreas and Czech, Thomas and Haberler, Christine and Slavc, Irene and Kasprian, Gregor and Dorfer, Christian and Furtner, Julia and Gojo, Johannes},
title = {Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method},
journal = {Acta Neuropathologica},
year = {2025},
doi = {10.1007/s00401-024-02842-7}
}
EUVIMED